CAS 928659-70-5: Eliglustat tartrate
Formula:C23H36N2O4C4H6O6
InChI:InChI=1S/C23H36N2O4.C4H6O6/c1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20;5-1(3(7)8)2(6)4(9)10/h10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26);1-2,5-6H,(H,7,8)(H,9,10)/t19-,23-;1-,2-/m11/s1
InChI key:InChIKey=VNGQLUTVKDPUJS-VUBSCCJGSA-N
SMILES:[C@@H]([C@@H](CN1CCCC1)NC(CCCCCCC)=O)(O)C=2C=C3C(=CC2)OCCO3.[C@@H]([C@H](C(O)=O)O)(C(O)=O)O
Synonyms:- Eliglustat hemitartrate
- Octanamide, N-[(1R,2R)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl]-, (2R,3R)-2,3-dihydroxybutanedioate (2:1)
- Eliglustat tartrate
- Genz 112638
Sort by
Found 7 products.
Eliglustat Tartrate
CAS:Controlled ProductFormula:(C23H36N2O4)•(C4H6O6)Color and Shape:NeatMolecular weight:2404.5415009Eliglustat hemitartrate
CAS:Eliglustat hemitartrate is a drug that inhibits the enzyme glucosylceramide synthase, which is involved in the production of glucosylceramide. Eliglustat hemitartrate is used to treat Gaucher disease, a rare genetic disorder where fatty substances accumulate in the liver and spleen. Eliglustat hemitartrate has been shown to reduce the levels of glucosylceramide in patients with Gaucher disease and may be an effective treatment for this condition. It also has been shown to inhibit P-glycoprotein (P-gp), which may allow more eliglustat to enter cells.Formula:C50H78N4O14Purity:Min. 98 Area-%Color and Shape:PowderMolecular weight:959.17 g/molEliglustat (Tartrate)
CAS:Formula:C50H78N4O14Purity:98%Color and Shape:SolidMolecular weight:959.1727Eliglustat hemitartrate
CAS:Eliglustat hemitartrate (Genz-112638) , with an IC50 of 24 nM, is a specific, potent, oral active glucocerebral glycosidase inhibitor.Formula:C25H39N2O7Purity:99.71%Color and Shape:SolidMolecular weight:479.59Ref: TM-T11176
1mg34.00€5mg64.00€10mg85.00€25mg116.00€50mg153.00€100mg273.00€200mg398.00€1mL*10mM (DMSO)89.00€
